Search
Sionna Therapeutics Inc
SIONAdd to Watchlist
5.230USD
-0.280-5.08%
Close 09-24 16:00（ET）
236.13MMarket Cap
LossP/E TTM
About Sionna Therapeutics Inc Company
Sionna Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on researching and developing novel medicines for cystic fibrosis. It is advancing a pipeline of small molecules engineered to correct the defects caused by the F508del genetic mutation, which resides in nucleotide-binding domain 1 (NBD1). It is conducting ongoing Phase I trials of its two highly potent NBD1 stabilizers, SION-719 and SION-451, evaluating the safety, tolerability and pharmacokinetic (PK) profile of single and multiple ascending doses in healthy subjects. It is also developing a portfolio of cystic fibrosis transmembrane conductance regulator (CFTR) modulators designed to work synergistically with its NBD1 stabilizers to improve CFTR function. Its portfolio also includes Galicaftor (SION-2222) and SION-2851, which are TMD1-directed CFTR correctors; SION-109, an ICL4-directed CFTR corrector, and Navocaftor (SION-3067), is a clinical-stage potentiator of CFTR gating activity.
Sionna Therapeutics Inc Profile
Ticker SymbolSION
Company nameSionna Therapeutics Inc
IPO dateFeb 07, 2025
CEOCloonan (Michael)
Number of employees41
Security typeOrdinary Share
Fiscal year-endFeb 07
Address21 Hickory Drive, Suite 500
CityWALTHAM
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code02451
Phone16178192020
Websitehttps://www.sionnatx.com/
Ticker SymbolSION
IPO dateFeb 07, 2025
CEOCloonan (Michael)
Company Executives of Sionna Therapeutics Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Michael (Mike) Cloonan
Mr. Michael (Mike) Cloonan
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
547.34K
--
Mr. Michael (Mike) Cloonan
Mr. Michael (Mike) Cloonan
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
547.34K
--
Mr. Michael (Mike) Cloonan
Mr. Michael (Mike) Cloonan
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
547.34K
--
Ms. Jennifer Fitzpatrick, J.D.
Ms. Jennifer Fitzpatrick, J.D.
Chief Legal Officer, Head of Program Management
Chief Legal Officer, Head of Program Management
56.27K
--
Ms. Jennifer Fitzpatrick, J.D.
Ms. Jennifer Fitzpatrick, J.D.
Chief Legal Officer, Head of Program Management
Chief Legal Officer, Head of Program Management
56.27K
--
Ms. Jennifer Fitzpatrick, J.D.
Ms. Jennifer Fitzpatrick, J.D.
Chief Legal Officer, Head of Program Management
Chief Legal Officer, Head of Program Management
56.27K
--
Ms. Elena H. Ridloff
Ms. Elena H. Ridloff
Chief Financial Officer, Chief Business Officer
Chief Financial Officer, Chief Business Officer
--
--
Mr. Paul J. Clancy
Mr. Paul J. Clancy
Independent Chairman of the Board of Director
Independent Chairman of the Board of Director
--
--
Dr. Charlotte McKee, M.D.
Dr. Charlotte McKee, M.D.
Chief Medical Officer, Head of Research and Development
Chief Medical Officer, Head of Research and Development
--
--
Dr. Bruce L. Booth
Dr. Bruce L. Booth
Independent Director
Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Michael (Mike) Cloonan
Mr. Michael (Mike) Cloonan
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
547.34K
--
Mr. Michael (Mike) Cloonan
Mr. Michael (Mike) Cloonan
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
547.34K
--
Mr. Michael (Mike) Cloonan
Mr. Michael (Mike) Cloonan
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
547.34K
--
Ms. Jennifer Fitzpatrick, J.D.
Ms. Jennifer Fitzpatrick, J.D.
Chief Legal Officer, Head of Program Management
Chief Legal Officer, Head of Program Management
56.27K
--
Ms. Jennifer Fitzpatrick, J.D.
Ms. Jennifer Fitzpatrick, J.D.
Chief Legal Officer, Head of Program Management
Chief Legal Officer, Head of Program Management
56.27K
--
Ms. Jennifer Fitzpatrick, J.D.
Ms. Jennifer Fitzpatrick, J.D.
Chief Legal Officer, Head of Program Management
Chief Legal Officer, Head of Program Management
56.27K
--
FAQs
Who are the top five shareholders of Sionna Therapeutics Inc?
The top five shareholders of Sionna Therapeutics Inc are: Mr. Michael (Mike) Cloonan
How many institutions hold shares of Sionna Therapeutics Inc (SION)?
As of 2026Q1, 183 institutions hold shares of Sionna Therapeutics Inc, with a combined market value of approximately 46.20M, accounting for 102.34% of the total shares. Compared to 2025Q4, institutional shareholding has increased by 5837190.00.